GLPG-3121 / Lakefront Biotherapeutics, Gilead - LARVOL DELTA

First key steps in pipeline rebuild and strong commercial progress in H1 2022 (GlobeNewswire) - "Galapagos NV...today announced its first half-year 2022 financial results...Pipeline update:...Discontinued development of 4 early-stage programs as part of ongoing scientific and strategic exercise: GLPG3121, a local release formulation JAK1/TYK2 inhibitor with potential in inflammatory diseases; GLPG0555, a JAK1 inhibitor evaluated in osteoarthritis; GLPG4586, a compound with undisclosed mode of action directed toward fibrosis; and GLPG4716, a chitinase inhibitor directed toward idiopathic pulmonary fibrosis"

Discontinued • Idiopathic Pulmonary Fibrosis • Inflammatory Bowel Disease • Osteoarthritis

A Study to Evaluate How Well Single and Multiple Doses of GLPG3121-modified Release Formulation Are Tolerated in Healthy, Adult Subjects (clinicaltrials.gov) - P1; N=50; Completed; Sponsor: Galapagos NV; Recruiting ➔ Completed

Clinical • Trial completion

A Study to Evaluate How Well Single and Multiple Doses of GLPG3121-modified Release Formulation Are Tolerated in Healthy, Adult Subjects (clinicaltrials.gov) - P1; N=56; Recruiting; Sponsor: Galapagos NV; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open

A Study to Evaluate How Well Single and Multiple Doses of GLPG3121-modified Release Formulation Are Tolerated in Healthy, Adult Subjects (clinicaltrials.gov) - P1; N=56; Not yet recruiting; Sponsor: Galapagos NV

Clinical • New P1 trial